WJP VICOM Ltd
- 1.350
- 0.0000.00%
VICOM Ltd News
Weikang Pharmaceutical (300878.SZ) plans to pay 2.5 yuan for 10 shares to be deducted from interest on May 29
Weikang Pharmaceutical (300878.SZ) announced that the company's 2023 equity distribution plan: a cash dividend of 2.50 yuan (tax included) for every 10 shares to all shareholders; the exclusion date is: May 29, 2024.
Investors in VICOM (SGX:WJP) Have Unfortunately Lost 27% Over the Last Three Years
Vicom Q1 Net Profit up 1.3% to S$6.9 Million
VEHICLE inspection company Vicom : WJP 0% posted a net profit of S$6.9 million in the first quarter of its 2024 fiscal year ended March, a mere 1.3 per cent increase from the same period last year.
Vicom Ltd Holds Successful Hybrid 43rd AGM
The A-share assisted reproduction sector generally fell by more than 9%
Gelonghui, May 10 | Kaineng Health and Dajia Weikang all fell more than 9%, Xiangxue Pharmaceutical fell nearly 9%, Shuangcheng Pharmaceutical fell more than 7%, and Zhongyuan Kyowa, Anke Biotech, Lanwei Medicine, and Hanyu Pharmaceutical all fell more than 5%.
The concept of assisted reproduction soared across the board. Dajia Weikang rose more than 16%, Hanshang Group's straight-line rise hit a standstill, and Xiangxue Pharmaceutical and Yuexin Health followed suit.
The concept of assisted reproduction soared across the board. Dajia Weikang rose more than 16%, Hanshang Group's straight-line rise hit a standstill, and Xiangxue Pharmaceutical and Yuexin Health followed suit.
Changes in the A-share baby concept boosted Dajia Weikang by more than 10%
Glonghui, May 9 | Dajia Weikang surged more than 10%, followed by Kangzhi Pharmaceutical, Lanwei Medical, Yuexin Health, Jinrabi, and Xinguang Pharmaceutical. According to the news, the National Health and Health Commission will hold a press conference at 15:00 on May 9 to introduce the “Implementing the Requirements for High-Quality Population Development and Actively Establishing a Fertility Support Policy System”.
Express News | Changes in the baby concept led to a sharp rise of more than 10%
The A-share pharmaceutical commercial sector reached as high as Gaveikang and rose more than 10%
Gelonghui, May 9 | Dajia Weikang rose more than 10%, Jianzhijia rose more than 6%, and Sinopharm, Yifeng Pharmacy, and Haiwang Biotech followed suit.
The pharmaceutical business sector fluctuated and strengthened, and Dajia Weikang rose more than 10%
The pharmaceutical business sector fluctuated and strengthened. Dajia Weikang rose more than 10%, Jianzhijia rose more than 6%, and Sinopharm, Yifeng Pharmacy, and Haiwang Biotech followed suit.
Weikang Pharmaceutical (300878.SZ) announced its 2023 annual results, with a net loss of 8.038,600 yuan, a year-on-year profit to loss
Weikang Pharmaceutical (300878.SZ) released its 2023 annual report. The company achieved revenue of 520 million yuan during the reporting period, a decrease of 2.41% over the previous year. The net loss attributable to shareholders of the listed company was RMB 8,038,600, a year-on-year change of profit to loss. The net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was 25.217,500 yuan, a year-on-year profit to loss. Basic earnings per share - 0.06 yuan/share, and it is proposed to distribute a cash dividend of 2.50 yuan (tax included) for every 10 shares to all shareholders.
Express News | Weikang Pharmaceutical: Net profit of 243.35 million yuan in the first quarter decreased 11.6% year on year
Here's Why We're Wary Of Buying VICOM's (SGX:WJP) For Its Upcoming Dividend
Dajia Weikang (301126.SZ) announced first-quarter results, net profit of 19.436,900 yuan, an increase of 27.14%
Dajia Weikang (301126.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 1.28 billion yuan, an increase of 46.06% over the previous year. Net profit attributable to shareholders of listed companies was 19.4369 million yuan, an increase of 27.14% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 19.3812 million yuan, an increase of 31.45% over the previous year.
Express News | The Zhejiang Securities Regulatory Bureau ordered corrections and issued a warning letter against Zhejiang Weikang Pharmaceutical
Shareholders May Be More Conservative With VICOM Ltd's (SGX:WJP) CEO Compensation For Now
Vicom Ltd Prepares for Hybrid 43rd AGM
VICOM Ltd's (SGX:WJP) Top Owners Are Public Companies With 67% Stake, While 27% Is Held by Individual Investors
Express News | Dajia Weikang establishes a large pharmacy chain including health food sales business
Dajia Weikang (301126.SZ) plans to spend 10 million yuan to 15 million yuan to implement a repurchase
Dajia Weikang (301126.SZ) announced that the company plans to use its own funds to repurchase the company department through centralized bidding transactions...
Analysis
Price Target
No Data
